Virion Therapeutics Announces Encouraging Phase 1b Immunogenicity Data of New HBV Treatment VRON-0200 at EASL Congress.

Kangpu Biopharmaceuticals recently revealed that the U.S. Food and Drug Administration has granted approval for a Phase II/III clinical trial investigating KPG-121 in combination with Abiraterone.

AbbVie has reported that the inaugural patient has received treatment with the experimental ABBV-383 in the CERVINO Phase 3 clinical trial.

Jun 12th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Amgen announces successful phase 3 trial results for Uplizna® (inebilizumab-cdon) in treating immunoglobulin G4-related disease (IgG4-RD).

Boston Pharmaceuticals Unveils Data at EASL Congress 2024 Demonstrating BOS-580, a Long-acting FGF21 Analogue, Enhances Lipid Profiles in Phenotypic MASH Patients.

Nutcracker Therapeutics Showcases Improved Efficacy of B Cell Lymphoma Drug Candidate NTX-472 at 2024 ASCO Meeting.

6.3-6.9 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

Accutar Biotechnology, Inc. has shared findings from an ongoing Phase 1 clinical trial of AC699.

Jun 7th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The European Commission has approved Biogen's QALSODY® (tofersen), a pioneering treatment for a rare genetic type of ALS.

Immunocore reveals new Phase 1 results for brenetafusp (IMC-F106C), a bispecific ImmTAC targeting PRAME, in melanoma patients previously treated with immune checkpoint inhibitors at ASCO 2024.